|
SMURF1 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.276400E-01 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.524600E-01 |
| Normal-vs-Stage2 |
3.586800E-01 |
| Normal-vs-Stage3 |
7.435200E-01 |
| Normal-vs-Stage4 |
5.830400E-01 |
| Stage1-vs-Stage2 |
3.013000E-01 |
| Stage1-vs-Stage3 |
7.320800E-01 |
| Stage1-vs-Stage4 |
5.564200E-01 |
| Stage2-vs-Stage3 |
2.853400E-01 |
| Stage2-vs-Stage4 |
2.195600E-01 |
| Stage3-vs-Stage4 |
7.944000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.095600E-01 |
| Normal-vs-AfricanAmerican |
4.535600E-01 |
| Normal-vs-Asian |
6.003800E-01 |
| Caucasian-vs-AfricanAmerican |
6.645200E-01 |
| Caucasian-vs-Asian |
9.159000E-01 |
| AfricanAmerican-vs-Asian |
7.563800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.375000E-01 |
| Normal-vs-Female |
8.372600E-01 |
| Male-vs-Female |
6.491400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.618600E-01 |
| Normal-vs-Age(41-60Yrs) |
9.938200E-01 |
| Normal-vs-Age(61-80Yrs) |
2.881400E-01 |
| Normal-vs-Age(81-100Yrs) |
7.122600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.151000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.027700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.879200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.473000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.822800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.790000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.532400E-01 |
| Classical-VS-Follicular |
1.84507964462455E-12 |
| Classical-VS-Other |
4.375600E-02 |
| Classical-VS-Normal |
4.679700E-02 |
| Tall-VS-Follicular |
3.884500E-03 |
| Tall-VS-Other |
1.784180E-01 |
| Tall-VS-Normal |
7.882400E-01 |
| Follicular-VS-Other |
8.028200E-01 |
| Follicular-VS-Normal |
5.59549999999964E-05 |
| Other-VS-Normal |
8.153500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.748590E-01 |
| Normal-vs-N1 |
9.800200E-01 |
| N0-vs-N1 |
2.927600E-01 |
|
|
